Robert A. Fenstermaker

Robert A. Fenstermaker

Auto-generated profile, based on publicly available information

Robert A. Fenstermaker

Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
DRDavid A. Reardon
David A. Reardon
AAAjay P. Abad
Ajay P. Abad
WCWilliam T. Curry
William T. Curry
EWEric T. Wong
Eric T. Wong
RFRobert A. Fenstermaker
Robert A. Fenstermaker
PURPOSE: Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557 ). METHODS: Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 μg once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed. RESULTS: SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients. CONCLUSION: SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.

30 August 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
RFRobert A. Fenstermaker
Robert A. Fenstermaker
MCMichael J. Ciesielski
Michael J. Ciesielski
JQJingxin Qiu
Jingxin Qiu
NYNuo Yang
Nuo Yang
CFCheryl L. Frank
Cheryl L. Frank
AHAlan D. Hutson
Alan D. Hutson
Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as human glioma cells ex vivo. The current clinical study was conducted to test safety, immunogenicity and clinical effects of the vaccine. Recurrent malignant glioma patients whose tumors were survivin-positive, and who had either HLA-A*02 or HLA-A*03 MHC class I allele-positivity, were given subcutaneous injections of SurVaxM (500 μg) in Montanide ISA 51 with sargramostim (100 μg) at 2-week intervals. SurVaxM was well tolerated with mostly grade one adverse events (AE) and no serious adverse events (SAE) attributable to the study drug. Six patients experienced local injection site reactions; three patients reported fatigue (grades 1 and 2), and 2 patients experienced myalgia (grade 1). Six of eight immunologically evaluable patients developed both cellular and humoral immune responses to vaccine. The vaccine also stimulated HLA-A*02, HLA-A*03 and HLA-A*24 restricted T cell responses. Three patients maintained a partial clinical response or stable disease for more than 6 months. Median progression-free survival was 17.6 weeks, and median overall survival was 86.6 weeks from study entry with seven of nine patients surviving more than 12 months.

7 December 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PGPhillip M. Galbo
Phillip M. Galbo
AMAnne Tranberg Madsen
Anne Tranberg Madsen
YLYang Liu
Yang Liu
MPMou Peng
Mou Peng
YWYao Wei
Yao Wei
DZDeyou Zheng
Deyou Zheng
Purpose: The abundance and biological contribution of cancer-associated fibroblasts (CAF) in glioblastoma (GBM) are poorly understood. Here, we aim to uncover its molecular signature, cellular roles, and potential tumorigenesis implications. Experimental Design: We first applied single-cell RNA sequencing (RNA-seq) and bioinformatics analysis to identify and characterize stromal cells with CAF transcriptomic features in human GBM tumors. Then, we performed functional enrichment analysis and in vitro assays to investigate their interactions with malignant GBM cells. Results: We found that CAF abundance was low but significantly correlated with tumor grade, poor clinical outcome, and activation of extracellular matrix remodeling using three large cohorts containing bulk RNA-seq data and clinical information. Proteomic analysis of a GBM-derived CAF line and its secretome revealed fibronectin (FN1) as a critical candidate factor mediating CAF functions. This was validated using in vitro cellular models, which demonstrated that CAF-conditioned media and recombinant FN1 could facilitate the migration and invasion of GBM cells. In addition, we showed that CAFs were more abundant in the mesenchymal-like state (or subtype) than in other states of GBMs. Interestingly, cell lines resembling the proneural state responded to the CAF signaling better for the migratory and invasive phenotypes. Conclusions: Overall, this study characterized the molecular features and functional impacts of CAFs in GBM, alluding to novel cell interactions mediated by CAFs in the GBM microenvironment.

10 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
PGPhillip M. Galbo
Phillip M. Galbo
MCMichael J. Ciesielski
Michael J. Ciesielski
SFSheila Figel
Sheila Figel
OMOrla Maguire
Orla Maguire
JQJingxin Qiu
Jingxin Qiu
RFRobert A. Fenstermaker
Robert A. Fenstermaker
Circulating CD9/GFAP/survivin exosomes in malignant glioma patients following survivin vaccination Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination

1 May 2004 in Cancer Control
Verified
Journal Article
Open access
PDF file
RFRobert A. Fenstermaker
Robert A. Fenstermaker
MCMichael J. Ciesielski
Michael J. Ciesielski
Despite advances in surgery, radiation therapy, and chemotherapy, only modest improvement has been achieved in the survival of patients with malignant gliomas. The authors review the immunologic aspects of gliomas, potential targets for therapy, and issues surrounding current immunotherapeutic strategies directed against malignant gliomas. The blood-brain barrier and the purported immunological privilege of the brain are not necessarily insurmountable obstacles to effective immunotherapy for brain tumors. Preclinical studies suggest a number of potential therapeutic avenues. Translational studies offer the prospect of providing substantial new information about immunological trafficking in the nervous system and suggesting the most fruitful approaches to immunotherapy for malignant gliomas. More effective adjuvant treatments for malignant gliomas are needed. The applicability of immunological approaches in the treatment of these tumors warrants continued study.

15 November 2002
Verified
Journal Article
Closed access
WYWeilian Yang
Weilian Yang
RBRolf F Barth
Rolf F Barth
DADianne M Adams
Dianne M Adams
MCMichael J Ciesielski
Michael J Ciesielski
RFRobert A Fenstermaker
Robert A Fenstermaker
MCMichael A Caligiuri
Michael A Caligiuri